Hospital/Center,City,Country,Condition(s),Study Title,NCT ID,Location Status,Overall Officials,Central Contacts,Site Contacts,Site Investigator(s)
,Innsbruck,Austria,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Innsbruck,Austria,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Antwerp University hospital,Antwerp,Belgium,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Antwerpen,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Hôpital Erasme,Brussels,Belgium,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
UZA,Edegem,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
University Hospital Antwerp,Edegem,Belgium,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
,Esneux,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
CHU de Liège,Esneux,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Centre Hospitalier Universitaire de Liège Ourthe Ambléve,Esneux,Belgium,Bladder Dysfunction; Multiple Sclerosis,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,NCT00913510,,"PRINCIPAL_INVESTIGATOR: Clare Fowler, Prof. (University College, London)",,,
Ourthe-Amblève,Esneux,Belgium,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Fraiture-en-Condroz,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Gent,Belgium,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Gent,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Universitair Ziekenhuis Gent,Gent,Belgium,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
,Ghent,Belgium,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
UZ Gent,Ghent,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Centre Hospitalier Regional de Huy,HUY,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Leuven,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
UZ Gasthuisberg,Leuven,Belgium,Bladder Dysfunction; Multiple Sclerosis,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,NCT00913510,,"PRINCIPAL_INVESTIGATOR: Clare Fowler, Prof. (University College, London)",,,
UZ Leuven,Leuven,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"Urology, University Hospitals KU Leuven",Leuven,Belgium,Painful Bladder Syndrome; Interstitial Cystitis,Prospective Randomised Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of Painful Bladder Syndrome/ Interstitial Cystitis,NCT04268810,,"PRINCIPAL_INVESTIGATOR: Dirk JM De Ridder, MD, PhD (University Hospitals KU Leuven)",,,
,Liege,Belgium,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Melsbroek,Belgium,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Maria Ziekenhuis Noord-Limburg,Overpelt,Belgium,Urinary Incontinence,Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium,NCT02072928,,STUDY_DIRECTOR: Medical Director (Allergan),,,
National MS Center,Steenokkerzeel,Belgium,Catheter Related Infections,Pilot Study to Evaluate the Efficacy of Antiseptic Bladder Lavage Versus Pulsatile Lavage With Physiologic Serum in Catheterized Patients With Asymptomatic Bacteriuria With Uropathogens.,NCT01772875,,"PRINCIPAL_INVESTIGATOR: Dirk De Ridder, Prof. (National MS Center Belgium & University Hospitals KU Leuven)",,,
,Ostrava,Czech Republic,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Brno,Czechia,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Fakultní Nemocnice Brno,Brno,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Ceske Budejovice,Czechia,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
"Karlovarska krajska nemocnice, a.s.",Karlovy Vary,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Krajská Nemocnice Liberec, a.s.",Liberec,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Olomouc,Czechia,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Uromedical Center s.r.o.,Olomouc,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Ostrava,Czechia,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
University Hospital Ostrava,Ostrava,Czechia,Multiple Sclerosis; Lower Urinary Tract Symptoms,The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related Quality of Life in Multiple Sclerosis Patients,NCT06218927,RECRUITING,"PRINCIPAL_INVESTIGATOR: Radek Paus Sýkora, MD (University Hospital Ostrava); STUDY_DIRECTOR: Jan Krhut, prof.,MD,PhD (University Hospital Ostrava)",,"CONTACT: Jiří Hynčica; PRINCIPAL_INVESTIGATOR: Radek Paus Sýkora, MD; SUB_INVESTIGATOR: Jan Krhut, prof.,MD,PhD; SUB_INVESTIGATOR: Tomáš Rychlý, MD",
University Hospital Ostrava,Ostrava,Czechia,Lower Urinary Tract Symptoms; Multiple Sclerosis,Onset of Lower Urinary Tract Symptoms in Multiple Sclerosis Patients,NCT06226831,RECRUITING,"PRINCIPAL_INVESTIGATOR: Jan Krhut, prof.,MD, PhD (University Hospital Ostrava)",CONTACT: Jiří Hynčica,"CONTACT: Jiří Hynčica; PRINCIPAL_INVESTIGATOR: Jan Krhut, prof.,MD,PhD; SUB_INVESTIGATOR: Barbora Skugarevská, MD",
,Prague,Czechia,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Faculty Hospital Motol,Praha,Czechia,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Recordati Investigative Site,Praha,Czechia,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
THOMAYER Faculty Hospital,Praha,Czechia,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Thomayerova nemocnice,Praha,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Fakultní nemocnice Královské Vinohrady,Praha 10,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Všeobecná fakultní nemocnice v Praze,Praha 2,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Fakultní Nemocnice v Motole,Praha 5,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Urologicka Ordinace s.r.o.,Sternberk,Czechia,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Department of Urology, Aarhus University Hospital, Section Skejby",Aarhus,Denmark,"Myelomeningocele; Bladder, Neurogenic",Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele,NCT00175123,,"PRINCIPAL_INVESTIGATOR: Bettina Jorgensen, MD (Department of Urology, Aarhus University Hospital)",,,
"Department of Urology, Rigshospitalet",Copenhagen,Denmark,Spinal Cord Injuries; Enlarged Prostate With Lower Urinary Tract Symptoms,Exploratory Study Investigating Urodynamic Parameters During Catheterisation,NCT03337048,,STUDY_DIRECTOR: Nazarena Mazarro (Vice president Medical Affairs),,,
"Copenhagen University Hospital, Glostrup",Glostrup,Denmark,Stroke; Urinary Incontinence,Six Months Follow-Up of Pelvic Floor Muscle Training in Women With Urinary Incontinence After Stroke,NCT00258037,,"PRINCIPAL_INVESTIGATOR: Sigrid G Tibaek, MSc., Pt (Copenhagen University Hospital, Glostrup)",,,
"Dept. of physiotherapy and occupational therapy, Glostrup University Hospital, Copenhagen",Glostrup,Denmark,Male; Stroke; Urinary Incontinence,The Effect of Pelvic Floor Muscle Training on Lower Urinary Tract Symptoms (LUTS) in Men With Stroke,NCT01042249,,,,,
"Department of Gynaecology and Obstetrics, Herlev University Hospital",Herlev,Denmark,Spinal Cord Injury; Urinary Incontinence,The Effect of Pelvic Floor Muscle Training and Neuromuscular Electrical Stimulation on Urinary Incontinence and Quality of Life in Women With Spinal Cord Injury,NCT02427230,,"PRINCIPAL_INVESTIGATOR: Marlene Elmelund, MD (Clinic for Spinal Cord Injuries, Glostrup University Hospital/Rigshospitalet and Department of Gynaecology and Obstetrics, Herlev University Hospital); STUDY_DIRECTOR: Fin Biering-Sørensen, MD DMSc Prof (Clinic for Spinal Cord Injuries, Glostrup University Hospital/Rigshospitalet); STUDY_DIRECTOR: Niels Klarskov, MD Lecturer (Department of Gynaecology and Obstetrics, Herlev University Hospital)",,,
Odense University Hospital,Odense,Denmark,Neurogenic Dysfunction of the Urinary Bladder; Multiple Sclerosis; Sacral Neuromodulation; Bowel Dysfunction; Sexual Dysfunction; Quality of Life,"Sacral Neuromodulation for Patients With Multiple Sclerosis With Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial.",NCT05380856,RECRUITING,PRINCIPAL_INVESTIGATOR: Hanne Kobberø (Odense University Hospital); STUDY_DIRECTOR: Mads H Poulsen (Odense University Hospital); STUDY_CHAIR: Morten Blaabjerg (Odense University Hospital); STUDY_CHAIR: Helle H Nielsen (Odense University Hospital); STUDY_CHAIR: Mikkel Fode (Herlev/Gentofte),CONTACT: Hanne Kobberø; CONTACT: Mads H Poulsen,CONTACT: Hanne Kobberø; CONTACT: Mads H Poulsen; PRINCIPAL_INVESTIGATOR: Hanne Kobberø,
Urology Department Zealand University Hospital,Roskilde,Denmark,Virtual Reality; Education; Bladder Cancer,Effect of Motor-imagery in Simulator-based Training in Transurethral Resection of Bladder Tumors - a Randomized Trial,NCT03864302,,"PRINCIPAL_INVESTIGATOR: Sarah Bube, MD (Zeland Region)",,,
Centre Hospitalier Universitaire de Besançon,Besançon,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Unité de Médecine Physique et Réadaptation - CHU Jean Minjoz,Besançon,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Centre Hospitalier Universitaire De Bordeaux,Bordeaux,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Centre Hospitalier Universitaire de Bordeaux | Pellegrin Hospital - Urology Department,Bordeaux,France,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Service de Médecine Physique et Réadaptation - Hôpital Pellegrin,Bordeaux,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
"Neurochirurgie A - Hôpital Pellegrin , Place Amélie Raba-Léon",Bordeaux Cedex,France,Spinal Cord Injuries; Neurogenic Bladder Disorder; Paraplegia; Quadriplegia,Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord,NCT00221767,,"PRINCIPAL_INVESTIGATOR: Jean-Rodolphe Vignes, Doctor (University Hospital, Bordeaux); STUDY_CHAIR: Geneviève Chêne, Professor (University Hospital, Bordeaux)",,,
Centre Hospitalier Régional Et Universitaire De Brest,Brest,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
,Caen,France,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Centre Hospitalier Universitaire De Caen Normandie,Caen,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Centre Hospitalier Universitaire de Clermont-Ferrand,Clermont-Ferrand,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Clermont-Ferrand University Hospital,Clermont-Ferrand,France,"Neurogenic Bladder Disorder; Spina Bifida; Complications of Surgical Procedures or Medical Care; Child, Only; Bladder Dysfunction",Surgical Complications After Bladder Augmentation in Children: a Retrospective Study About 87 Patients,NCT06733194,,"PRINCIPAL_INVESTIGATOR: Christelle Destinval (University Hospital, Clermont-Ferrand)",,,
"University Hospital, Clermont-Ferrand",Clermont-Ferrand,France,"Incontinence; Bladder Dysfunction; Spina Bifida; Neurogenic Bladder Disorder; Child, Only",Management of Patients Under 18 Years of Age Who Have Had Bladder Neck Procedures,NCT06734390,,,,,
"University Hospital, Clermont-Ferrand",Clermont-Ferrand,France,"Calculi, Urinary; Neurogenic Bladder Disorder; Spina Bifida; Child, Only",Management of Patients Who Had Urolithiasis After Bladder Augmentation in Childhood,NCT06734403,,,,,
"University Hospital, Clermont-Ferrand",Clermont-Ferrand,France,"Neurogenic Bladder Disorder; Bladder Dysfunction; Spina Bifida; Urinary Incontinence Due to Urethral Sphincter Incompetence; Child, Only",Management of Patients Who Had an Artificial Urethral Sphincter by Laparotomy in Childhood,NCT06734429,,,,,
Centre Hospitalier De Colmar,Colmar,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
CHU Dijon Bourgogne,Dijon,France,Neurogenic Bladder,Multicentre Randomised Double-blind Superiority Trial With a Roll-over Phase to Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder,NCT06588010,RECRUITING,,CONTACT: Lionel PIROTH,CONTACT: Lionel PIROTH,
,Garches,France,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Garches,France,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Garches,France,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"Consultations maladies infectieuses et tropicales, Hôpital Raymond Poincaré",Garches,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Hopital Raymond Poincaré,Garches,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Hôpital Raymond-Poincaré,Garches,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Service de Médecine Physique et Réadaptation - Hôpital Raymond Poincaré,Garches,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Centre Hospitalier Universitaire Grenoble Alpes,Grenoble,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Centre Hospitalier Universitaire de Lille,Lille,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Hop Claude Huriez Chu Lille,Lille,France,Multiple Sclerosis; Lower Urinary Tract Symptoms,Efficacy and Safety of Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis Patients.,NCT04573673,RECRUITING,"PRINCIPAL_INVESTIGATOR: Xavier Biardeau, MD (University Hospital, Lille)","CONTACT: Xavier Biardeau, MD",CONTACT: ,
Hopital HURIET,Lille,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez,Lille Cedex,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Centre Hospitalier Et Universitaire De Limoges,Limoges,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Médecine Physique et Réadaptation - Groupe Hospitalier de l'institut Catholique de Lille - Hôpital Saint Philibert,Lomme,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Centre Hospitalier Universitaire de Lyon-Sud,Lyon,France,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
Hôpital Lyon Sud -Hospices Civils de Lyon,Lyon,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
,Marseille,France,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Assistance Publique Hopitaux de Marseille,Marseille,France,Neurogenic Bladder Due to Spinal Dysraphism,EVALUATION OF THE SAFETY AND EFFICACY OF ADJUSTABLE CONTINENT THERAPY FOR THE MANAGEMENT OF NEUROGENIC INCONTINENCE IN CHILDREN WITH SPINAL DYSRAPHISM.,NCT03351634,,STUDY_DIRECTOR: Urielle DESALBRES (ASSISTANTE PUBLIQUE HOPITAUX DE MARSEILLE),CONTACT: Alice FAURE; CONTACT: Claire MORANDO,CONTACT: Alice FAURE; CONTACT: Claire MORANDO,
Centre Hospitalier Régional De Marseille,Marseille,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Hopital de la conception,Marseille,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Hôpital de la Conception,Marseille CEDEX 5,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
ULorraine,Nancy,France,"Complications of Surgical Procedure; Neurogenic Bladder; Spina Bifida; Child, Only",Surgical Complications of Enterocystoplasty in Children: A Retrospective Monocentric Study About 39 Cases,NCT05840874,,,,,
CHU Hotel Dieu,Nantes,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Fondation Lenval Nice,Nice,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Groupe Hospitalo-Universitaire Pierre Caremau,Nimes Cedex 9,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
CHU de Nîmes,Nîmes,France,Multiple Sclerosis; Dysuria; Lower Urinary Tract Symptoms; Voiding Dysfunction; Urinary Retention,Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women,NCT05439902,RECRUITING,PRINCIPAL_INVESTIGATOR: Stéphane DROUPY (CHU de Nimes),CONTACT: Stéphane DROUPY,CONTACT: Anissa Megzari; SUB_INVESTIGATOR: Eric Thouvenot; SUB_INVESTIGATOR: Giovanni Castelnovo; PRINCIPAL_INVESTIGATOR: Stéphane Droupy; SUB_INVESTIGATOR: Kamel Ben Naoum,
Nîmes University Hospital,Nîmes,France,Spinal Cord Injuries; Urinary Diversion; Neurogenic Bladder,Long-term Evaluation of the Efficacy and Safety of a Continent Cutaneous Urinary Diversion in Spinal Cord Injury Patients,NCT04936217,RECRUITING,,,"CONTACT: HILAL AL RASHDI, Dr.; CONTACT: STEPHANE DROUPY, Pr.",
Hopital de la Source,Orleans,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Paris,France,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Assistance Publique Hopitaux de Paris | Pitie Salpetriere University Hospital - Urology Department,Paris,France,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
"Department of Neuro- Urology, Hôpital Tenon",Paris,France,Multiple Sclerosis; Lower Urinary Tract Symptoms; Voiding Disorders,Multiple Sclerosis and Voiding Symptoms: How to Assess?,NCT04928716,,"PRINCIPAL_INVESTIGATOR: Gérard Amarenco, PHD (Sorbonne Université, GRC 001, GREEN Groupe de Recherche en Neuro-Urologie, AP-HP, Hôpital Tenon, F-75020, Paris, France)",,,
"Department of Urology, Academic hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne Universités",Paris,France,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
Groupe Hospitalier La Pitié Salpetriere,Paris,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Hopital Pitie-Salpetriere,Paris,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Hopital Tenon,Paris,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Hôpital Necker Enfants Malades,Paris,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Hôpital TENON,Paris,France,Overactive Bladder,Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis,NCT05772637,RECRUITING,,"CONTACT: Claire Hentzen, MD; CONTACT: Gérard AMARENCO, MD, PhD","CONTACT: Claire HENTZEN, MD; PRINCIPAL_INVESTIGATOR: Claire Hentzen, MD",
Hôpital Trousseau (chirurgie viscérale pédiatrique et néonatale),Paris,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Hôpital Trousseau (médecine physique et de réadaptation pédiatrique),Paris,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Hôpital de la Pitié Salpétrière,Paris,France,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
INstitut Mutualiste Montsouris,Paris,France,Renal Cell Carcinoma; Bladder Cancer; MSI-H Cancer; Cancer,Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside,NCT06020651,RECRUITING,,"CONTACT: Isabelle Sauret, MBS","CONTACT: Mariana Mirabel, MD, PhD",
"Neurourology department, Hopital tenon",Paris,France,Neurogenic Bladder,French Version of the Short Form of Neurogenic Bladder Symptom Score: Cross-Cultural Adapta-tion and Validation.,NCT04902755,,,,,
Physical and Rehabilitation Medicine Pitié Salpêtrière Hospital,Paris,France,Urodynamic Exam; Neurologic Disorder,Does Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population - a Concordance Study Between Lying and Sitting Position,NCT05949567,RECRUITING,,,"CONTACT: Bertrand M PICHON, MD; CONTACT: Helene Ms Robert, MD; SUB_INVESTIGATOR: Matthieu M GRASLAND, MD; PRINCIPAL_INVESTIGATOR: Bertrand M PICHON, MD",
Rééducation Neurologique et Explorations Périnéales - Hôpital Rothschild,Paris,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
"Service de Neuro-urology, hôpital Tenon",Paris,France,Multiple Sclerosis; Lower Urinary Tract Symptoms; Gait,Effect of Need to Void on Gait Speed in Multiple Sclerosis,NCT03204747,,"PRINCIPAL_INVESTIGATOR: Gérard Amarenco, PhD (GREEN GRC-01, Neuro-urology, hôpital Tenon)",,,
"Service de Neuro-urology, hôpital Tenon",Paris,France,Lower Urinary Tract Symptoms; Cystometry; Multiple Sclerosis; Overactive Bladder; Overactive Detrusor,Reproductibility of Cystometry in Multiple Sclerosis Patient,NCT03451175,,"PRINCIPAL_INVESTIGATOR: Gerard AMARENCO, PhD (GREEN GRC-01, Neuro-urology, hôpital Tenon)",,,
"department of Neuro-Urology, Hôpital Tenon",Paris,France,"Gait Disorders, Neurologic; Urinary Incontinence, Urge; Multiple Sclerosis",Time to be Ready to Void: a New Tool to Assess the Time Needed to Perform Micturition for Patients With Multiple Sclerosis,NCT04024085,,"PRINCIPAL_INVESTIGATOR: Gérard Amarenco, PhD (Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France)",,,
"department of Neuro-Urology, Hôpital Tenon",Paris,France,Multiple Sclerosis; Anorectal Disorders; Bladder Dysfunction,"Effect of Need to Void on Rectal Sensory Function in Multiple Sclerosis, a Manometric Study",NCT04057222,,"PRINCIPAL_INVESTIGATOR: Gérard Amarenco, PUPH (Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France)",,,
"department of Neuro-Urology, Hôpital Tenon",Paris,France,Fall; Multiple Sclerosis; Lower Urinary Tract Symptoms,Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis,NCT04338646,,"PRINCIPAL_INVESTIGATOR: Gérard Amarenco, PhD (Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France)",,,
Hôpital Tenon,Paris Cedex 20,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Centre Hospitalier Lyon Sud Unité de Pharmacie Clinique Oncologique (essai clinique) Pavillon Marcel Bérard - Bât. 1G,Pierre-Bénite,France,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
Centre Hospitalier Lyon-Sud,Pierre-Bénite,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Ploemeur,France,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
CMRRF Kerpape,Ploemeur,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE,Ploemeur,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Centre Hospitalier Universitaire de Poitiers,Poitiers,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
CHU de Rennes - Hôpital Pontchaillou,Rennes,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Centre Hospitalier Universitaire de Rennes,Rennes,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Centre de Médecine Physique et Réadaptation Notre Dame de Lourdes,Rennes,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Centre hospitalier universitaire de Rennes,Rennes,France,Spina Bifida; Multiple Sclerosis; Spinal Cord Injury; Overactive Bladder,Urinary Markers of Detrusor Overactivity in Spina Bifida Patients,NCT02852317,,,,,
Service de Médecine Physique et Réadaptation - Hôpital Pontchaillou,Rennes,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
CHU Rouen - Hopital Charles Nicolle,Rouen,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Recordati Investigative Site,Rouen,France,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
CHU de ROUEN - Hôpital Charles Nicolle,Rouen Cedex,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Salouel,France,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Salouel,France,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Centre Hospitalier Universitaire De Saint Etienne,St Etienne,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Les Hopitaux Universitaires De Strasbourg,Strasbourg,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
Nouvel Hopital civil de Strasbourg,Strasbourg,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
CHU Toulouse - Hopital Rangueil,Toulouse,France,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Recordati Investigative Site,Toulouse,France,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
Service de médecine physique et réadapation Hopital de Rangueil,Toulouse,France,Multiple Sclerosis; Urinary Tract Infections; Bladder Dysfunction,"Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.",NCT00280592,,"STUDY_CHAIR: Jean-Michel Reymann, PhD (CHU Rennes); PRINCIPAL_INVESTIGATOR: Philippe Gallien, MD (CHU Rennes)",,,
Hôpital Rangueil,Toulouse Cedex 9,France,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Centre Hospitalier Régional Et Universitaire de Nancy,Vandoeuvre-les-Nancy,France,Spina Bifida,"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction: A Randomized, Prospective Controlled Multi-center Trial",NCT07027020,,,"CONTACT: Nicolas BERTE, Dr; CONTACT: Jean-Louis LEMELLE, Pr",,
ULorraine,Vandœuvre-lès-Nancy,France,"Neurogenic Bladder; Bladder Dysfunction; Spina Bifida; Child, Only",Place of Urinary Artificial Sphincter in Children With Neurogenic Bladder,NCT05858840,,"PRINCIPAL_INVESTIGATOR: Christelle Destinval, MD (University of Lorraine)",,,
ULorraine,Vandœuvre-lès-Nancy,France,"Incontinence, Urinary; Bladder Dysfunction; Spina Bifida; Neurogenic Bladder",Surgical Outcomes of Bladder Neck Procedures in Children With Neurogenic Bladder: a Retrospective Monocentric Study,NCT05861011,,"PRINCIPAL_INVESTIGATOR: Christelle Destinval, MD (University of Lorraine)",,,
,Bad Berka,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
inContAlert GmbH,Bayreuth,Germany,Monitoring of the Bladder Filling,Evaluation and Optimization of Machine Learning Algorithms for Individual Bladder Filling Level Prediction by a Sensor System,NCT05952700,,"STUDY_DIRECTOR: Jannik Lockl, Dr. (inContAlert GmbH)",,,
,Berlin,Germany,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Berlin,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
"St. Hedwig Hospital, Department of Urology",Berlin,Germany,Bladder Dysfunction; Multiple Sclerosis,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,NCT00913510,,"PRINCIPAL_INVESTIGATOR: Clare Fowler, Prof. (University College, London)",,,
Universitätsklinikum Bonn Klinik und Poliklinik für Urologie,Bonn,Germany,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Emmendingen,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Hagenow,Germany,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Halle,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Halle (Saale),Germany,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Hamburg,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Heidelberg,Germany,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Heidelberg,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Herne,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
"Marienhospital Herne, Klinikum der Ruhr-Universitaet Bochum",Herne,Germany,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
,Kiel,Germany,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Kiel,Germany,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Universitätsklinik Kiel,Kiel,Germany,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
,Lahr,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Mainz,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
Kliniken Maria Hilf GmbH - Krankenhaus St. Franziskus,Monchengladbach,Germany,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Novartis Investigative Site,Murnau,Germany,"Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic","A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy",NCT01598103,,STUDY_DIRECTOR: Novartis Pharmaceuticals (Novartis Pharmaceuticals),,,
,Mönchengladbach,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Mülheim,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
Universitätsklinikum Münster,Münster,Germany,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Städtisches Klinikum Neunkirchen,Neunkirchen,Germany,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
,Oberursel,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Planegg,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Tübingen,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
Klinik für Urologie Oberarzt-Sekretaria,Tübingen,Germany,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
,Villingen-Schwenningen,Germany,Multiple Sclerosis; Overactive Detrusor,"A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity",NCT00845338,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
,Thessaloniki,Greece,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00575016,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Nyiregyhaza,Hungary,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Sopron,Hungary,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Szeged,Hungary,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
University of Limerick,Limerick,Ireland,"Bladder Dysfunction; Neurogenic Bladder Dysfunction; Urinary Incontinence; Urinary Bladder, Overactive; Urinary Incontinence, Urge; Nocturia; Urinary Frequency More Than Once at Night; Lower Urinary Tract Symptoms; Multiple Sclerosis; Urinary Bladder, Neurogenic",Transcutaneous Tibial Nerve Stimulation for the Treatment of Bladder Storage Symptoms in People With Multiple Sclerosis: Protocol of a Single-arm Feasibility Study,NCT04528784,,"PRINCIPAL_INVESTIGATOR: Katie Robinson, PhD (University of Limerick)",,,
,Firenze,Italy,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Azienda Ospedaliero-Universitaria Careggi - Dipartimento Di Neuro-Urologia,Firenze,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Ospedale Careggi,Firenze,Italy,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
,Florence,Italy,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Careggi University Hospital,Florence,Italy,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
"Farmacia Istituto Ospedaliero ICOT ""Marco Pasquali""",Latina,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Milan,Italy,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Milan,Italy,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Niguarda Ospedale Ca' Granda,Milan,Italy,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
Prof. Giancarlo Comi,Milan,Italy,Overactive Bladder Syndrome; Multiple Sclerosis; Muscle Strain,"Efficacy of Isometric Contraction Exercises of Lower Limbs Muscles, in Modulating Neurological Control of Bladder Function in Patients With Multiple Sclerosis",NCT03322748,,"PRINCIPAL_INVESTIGATOR: Giancarlo Comi, MD (IRCCS San Raffaele)","CONTACT: Giancarlo Comi, MD; CONTACT: Valentina Grazioli, PT",,
Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia,Perugia,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Viale Oxford, 81",Roma,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Rome,Italy,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Tor Vergata University Hospital,Rome,Italy,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
"Ospedale ""Bolognini"" di Seriate",Seriate,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Torino,Italy,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Azienda Ospedaliera di Perugia - Ospedale Santa Maria della Misericordia,Udine,Italy,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Multiple Sclerosis Center of ASP 7 Ragusa,Vittoria,Italy,"Multiple Sclerosis; Urinary Bladder, Neurogenic",A Multicentre Observational Study for the Evaluation in Clinical Practice of the Initial Diagnostic-therapeutic Path of Urinary Disorders in Multiple Sclerosis,NCT05075642,,"PRINCIPAL_INVESTIGATOR: Carmela Leone, MD (Multiple Sclerosis Center of ASP7 Ragusa); STUDY_DIRECTOR: Antonello Giordano, MD (Multiple Sclerosis Center of ASP7 Ragusa)","CONTACT: Carmela Leone, MD; CONTACT: Antonello Giordano, MD","CONTACT: Carmela Leone, MD; CONTACT: Angela Vicenzino, Nurse; PRINCIPAL_INVESTIGATOR: Carmela Leone, MD; SUB_INVESTIGATOR: Salvatore Maria Cavalli, MD; SUB_INVESTIGATOR: Giuseppe Zelante, MD; SUB_INVESTIGATOR: Francesco Savoca, MD; SUB_INVESTIGATOR: Angela Vicenzino, Nurse; SUB_INVESTIGATOR: Marta Biondo, Nurse",
"Estetines Chirurgijos Centas, UAB",Kaunas,Lithuania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Vilnius University Hospital Santariskiu Klinikos,Vilnius,Lithuania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Amsterdam,Netherlands,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Amsterdam,Netherlands,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
VU University Medical Center,Amsterdam,Netherlands,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Apeldoorn,Netherlands,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Eindhoven,Netherlands,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Academisch Ziekenhuis,Maastricht,Netherlands,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
,Nijmegen,Netherlands,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Novartis Investigative Site,Nijmegen,Netherlands,"Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic","A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy",NCT01598103,,STUDY_DIRECTOR: Novartis Pharmaceuticals (Novartis Pharmaceuticals),,,
Radboud UMC,Nijmegen,Netherlands,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"UMC ST Radboud Nijmegen, Department of Urology",Nijmegen,Netherlands,Bladder Dysfunction; Multiple Sclerosis,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,NCT00913510,,"PRINCIPAL_INVESTIGATOR: Clare Fowler, Prof. (University College, London)",,,
Erasmus MC,Rotterdam,Netherlands,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Sunnaas Hospital,Nesoddtangen,Norway,"Spinal Cord Injuries; Urinary Bladder, Overactive","Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity",NCT01698138,,"PRINCIPAL_INVESTIGATOR: Lars Frich, MD, PhD (University of Oslo); PRINCIPAL_INVESTIGATOR: Ole Jacob Nilsen, MD (University of Oslo); PRINCIPAL_INVESTIGATOR: Thomas Glott, MD (Sunnaas Rehabilitation Hospital, Norway)",,,
Oslo University Hospital,Oslo,Norway,"Spinal Cord Injuries; Urinary Bladder, Overactive","Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity",NCT01698138,,"PRINCIPAL_INVESTIGATOR: Lars Frich, MD, PhD (University of Oslo); PRINCIPAL_INVESTIGATOR: Ole Jacob Nilsen, MD (University of Oslo); PRINCIPAL_INVESTIGATOR: Thomas Glott, MD (Sunnaas Rehabilitation Hospital, Norway)",,,
Sunnaas Rehabilitation Hospital,Oslo,Norway,"Spinal Cord Injuries; Urinary Bladder, Neurogenic",Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction,NCT06445426,,,,,
Wojewódzki Szpital Zespolony w Elblągu,Elblag,Poland,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Nzoz Neuro-Medic Poradnia Wielospecjalistyczna,Katowice,Poland,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Department of Urology Jagiellonian University,Kraków,Poland,Spinal Cord Injuries; Multiple Sclerosis,"Polish Translation and Validation of the Neurogenic Bladder Symptom Score (NBSS), Qualiveen and Short Form Qualiveen (SF-Qualiveen) Questionnaires",NCT04185792,,,,,
NZOZ Heureka,Piaseczno,Poland,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Recordati Investigative Site,Piaseczno,Poland,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
,Poznan,Poland,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"Department of Rehabilitation and Physiotherapy Rehabilitation,",Poznań,Poland,Spinal Cord Injuries; Neurogenic Bladder; Urodynamics,Urodynamic Evaluation Neurgenic Bladder in Patients After Spinal Cord Injury,NCT04231474,RECRUITING,"STUDY_DIRECTOR: Przemysław Lisiński, MPhD (Clinic Rehabilitation, University of Medical Sciences in Poznań)",CONTACT: Ewa Chlebuś,"CONTACT: Ewa Chlebuś, lek",
Recordati Investigative Site,Rzeszów,Poland,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
,Warsaw,Poland,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
NZOZ Centrum Medyczne Mazovia,Warszawa,Poland,Detrusor Muscle Hyperactivity,"A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.",NCT01357980,,STUDY_DIRECTOR: Ipsen Study Director (Ipsen),,,
Recordati Investigative Site,Warszawa,Poland,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
Szpital Kliniczny Dzieciątka Jezus w Warszawie,Warszawa,Poland,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Wroclaw,Poland,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
EuroMediCare Szpital Specjalistyczny z Przychodnią we Wrocławiu,Wroclaw,Poland,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Hospital de Braga,Braga,Portugal,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Centro Hospitalar do Alto Ave, EPE",Guimarães,Portugal,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
British Hospital,Lisboa,Portugal,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Porto,Portugal,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Porto,Portugal,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Porto,Portugal,Urinary Incontinence; Multiple Sclerosis; Neurogenic Bladder,Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS),NCT01600716,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"Centro Hospitalar de São João, EPE - Hospital de São João",Porto,Portugal,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António",Porto,Portugal,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Recordati Investigative Site,Porto,Portugal,Neurogenic Detrusor Overactivity,"Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study",NCT03482037,,"PRINCIPAL_INVESTIGATOR: Francisco Cruz, M.D. (Hospital São João, Urologia, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal)",,,
Gnosis Evomed,Bucharest,Romania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Hifu Terramed Conformal S.R.L,Bucharest,Romania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Spitalul Clinic Colentina,Bucharest,Romania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Spitalul Clinic Fundeni Bucureşti,Bucharest,Romania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Spitalul Clinic Judeţean Mureş,Târgu-Mureş,Romania,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Belgrade,Serbia,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00575016,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Martin,Slovakia,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Presov,Slovakia,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"University Rehabilitation Institute, Republic of Slovenia",Ljubljana,Slovenia,"Stroke, Ischemic; Stroke Hemorrhagic; Urinary Incontinence",Assessment and Treatment of Urinary Disorders in Patients in the Subacute Phase After Stroke,NCT04078373,RECRUITING,"PRINCIPAL_INVESTIGATOR: Nataša Bizovičar, MD, PhD (University Rehabilitation Institute, Republic of Slovenia)","CONTACT: Helena Burger, MD, PhD; CONTACT: Nataša Bizovičar, MD, PhD","CONTACT: Helena Burger, MD, PhD; CONTACT: Nataša Bizovičar, MD, PhD",
Complexo Hospitalario Universitario A Coruña,A Coruña,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Badalona,Spain,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
,Badalona,Spain,Erectile Dysfunction; Spinal Cord Injury,"Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE)",NCT00667966,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
Guttmann Institute,Badalona,Spain,Neurogenic Detrusor Overactivity; Spinal Cord Injury,Therapeutic Effects of Early and Late Onset Peripheral Pudendal Neurostimulation on Bladder Function and Autonomic Neuroplasticity in SCI - a Controlled European Multicenter Study,NCT01043848,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, MD (University of Zurich); PRINCIPAL_INVESTIGATOR: Martin Schubert, MD (Balgrist University Hospital)",,,
Fundacio Puigvert,Barcelona,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Fundació GAEM,Barcelona,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Hospital Universitario Vall d'Hebron,Barcelona,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Getafe,Spain,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Laura Martín Losada,Guadarrama,Spain,Urinary Incontinence,Efficacy of Prompted Voiding Therapy for Reverse the Urinary Incontinence Status in Elderly Patients Hospitalized in a Functional Recovery Ward.,NCT04117126,,PRINCIPAL_INVESTIGATOR: Laura Martin Losada (Hospital Guadarrama),,,
,La Coruna,Spain,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Hospital Universitario La Paz,Madrid,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,San Juan de Alicante,Spain,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Hospital Universitario Virgen del Rocío,Sevilla,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Tenerife,Spain,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Tenerife,Spain,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,Toledo,Spain,Erectile Dysfunction; Spinal Cord Injury,"Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE)",NCT00667966,,STUDY_DIRECTOR: Bayer Study Director (Bayer),,,
Hospital Universitari i Politècnic La Fe,Valencia,Spain,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Hospital Universitario y Politécnico La Fe,Valencia,Spain,Stress Urinary Incontinence,"Comparison of Efficacy and Side Effects Between the Obtryx and Solyx Band With 5-year Follow-up. Prospective, Randomized and Non-inferiority Study",NCT03916471,RECRUITING,PRINCIPAL_INVESTIGATOR: Marta Garcia (Instituto de Investigación y Politécnico La Fe),CONTACT: Maria Cortell,CONTACT: Laura Segura,
Hospital General de Villalba,Villalba,Spain,Relapsing-Remitting Multiple Sclerosis; Urinary Incontinence,Assessment of the Effectiveness of Guided by a Physiotherapist Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence (UI) in Patients With Relapsing-Remitting (RR) Multiple Sclerosis,NCT03000647,,"PRINCIPAL_INVESTIGATOR: Denise Cuevas, BSc (Universidad Rey Juan Carlos)",,,
"Spinal Cord Injury Unit, Sahlgrenska University Hospital",Göteborg,Sweden,"Bacteriuria, Intermittent Catheterization",Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine,NCT01782404,,"PRINCIPAL_INVESTIGATOR: Lena Rutberg, MD (Sahlgrenska University Hospital)",,,
"Spinal Cord Injury Unit, Skåne University Hospital",Höör,Sweden,"Bacteriuria, Intermittent Catheterization",Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine,NCT01782404,,"PRINCIPAL_INVESTIGATOR: Lena Rutberg, MD (Sahlgrenska University Hospital)",,,
"Spinal Cord Injury Unit, Linköping University Hospital",Linköping,Sweden,"Bacteriuria, Intermittent Catheterization",Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine,NCT01782404,,"PRINCIPAL_INVESTIGATOR: Lena Rutberg, MD (Sahlgrenska University Hospital)",,,
"Neurocentrum, Neurorehab, Norrlands Universitetssjukhus",Umeå,Sweden,"Bacteriuria, Intermittent Catheterization",Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine,NCT01782404,,"PRINCIPAL_INVESTIGATOR: Lena Rutberg, MD (Sahlgrenska University Hospital)",,,
Cantonal Hospital Aarau,Aarau,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
REHAB Basel,Basel,Switzerland,"Spinal Cord Injury, Acute","Transcutaneous Tibial Nerve Stimulation in Patients with Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: a Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial",NCT03965299,RECRUITING,"STUDY_CHAIR: Thomas M. Kessler, Prof. Dr. med. (University of Zurich); PRINCIPAL_INVESTIGATOR: Thomas M. Kessler, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Armin Curt, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Martin Brinkhof, Dr. (Swiss Paraplegic Research, Nottwil); PRINCIPAL_INVESTIGATOR: Jürgen Pannek, Prof. Dr. med. (Swiss Paraplegic Centre)","CONTACT: Thomas M. Kessler, Prof. Dr. med.; CONTACT: Martina D. Liechti, Dr. sc. ETH","CONTACT: Sandra Möhr, pract. med.; CONTACT: Sandra Möhr, pract. med.",
REHAB Basel,Basel,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
EOC - Regional Hospital Bellinzona and Valleys,Bellinzona,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
University Hospital Inselspital,Bern,Switzerland,Disorder of the Lower Urinary Tract,Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction Reveal Common Signalling Pathways Relevant for Disease Progression and Recovery,NCT02410876,,"PRINCIPAL_INVESTIGATOR: Fiona C Burkhard, MD (Insel Gruppe AG, University Hospital Bern); PRINCIPAL_INVESTIGATOR: Jürgen Pannek, MD (Swiss paraplegic center Nottwil)",,,
"Inselspital Bern, University Hospital",Berne,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
University Hospital Inselspital Berne,Berne,Switzerland,Refractory Neurogenic LUTD,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial",NCT02165774,,,,,
Centre Hospitalier Universitaire Vaudois,Lausanne,Switzerland,"Urinary Bladder, Neurogenic; Multiple Sclerosis",Injections of Botulinum Toxin a or Anticholinergic Treatment As First Line Therapy to Treat Neurogenic Overactive Bladder in Patients with Multiple Sclerosis,NCT04819360,,"PRINCIPAL_INVESTIGATOR: Brigitte Schürch, Prof. (Centre Hospitalier Universitaire Vaudois)",,,
Centre Hospitalier Universitaire Vaudois (CHUV),Lausanne,Switzerland,Spinal Cord Injuries (SCI); Spinal Cord Injury,Study on Preliminary Safety and Efficacy of Epidural Electrical Stimulation to Manage Lower Urinary Tract Dysfunction After Spinal Cord Injury,NCT06845904,RECRUITING,"PRINCIPAL_INVESTIGATOR: Jocelyne Bloch, MD (Centre hospitalier universitaire vaudois (CHUV))","CONTACT: Jocelyne Bloch, MD","CONTACT: Jocelyne Bloch, Prof. Dr.",
Centre hospitalier universitaire vaudois CHUV,Lausanne,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
"Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland",Lugano,Switzerland,Multiple Sclerosis,"A Prospective, Single Arm, Interventional, Self-controlled Pilot Study to Assess the Performance and Safety of the New Generation, Wireless, Implantable Tibial Nerve Stimulator System (eCoin™) for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis",NCT03753698,,"STUDY_DIRECTOR: Chiara Zecca, PD, MD (Ospedale Regionale di Lugano)",,,
"Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland",Lugano,Switzerland,"Multiple Sclerosis, Relapsing-Remitting",Prospective Single Centre Trial of Percutaneous Tibial Nerve Stimulation With the Implantable StimRouter Neuromodulation System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis,NCT04567264,,,,,
Schweizerisches Paraplegikerzentrum Nottwil,Nottwil,Switzerland,Neurogenic Detrusor Overactivity; Spinal Cord Injury,Therapeutic Effects of Early and Late Onset Peripheral Pudendal Neurostimulation on Bladder Function and Autonomic Neuroplasticity in SCI - a Controlled European Multicenter Study,NCT01043848,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, MD (University of Zurich); PRINCIPAL_INVESTIGATOR: Martin Schubert, MD (Balgrist University Hospital)",,,
Swiss Paraplegic Center,Nottwil,Switzerland,Spinal Cord Injury; Urinary Incontinence; Menstrual Cycle,Urine Incontinence Occurrence and Sexual Hormones in Women With Chronic Spinal Cord Injury/Disease - a Pilot Study,NCT06892080,RECRUITING,,"CONTACT: Jörg Krebs, Dr. med. vet. / PhD; CONTACT: Jürgen Pannek, Prof. Dr. med.","CONTACT: Jürgen Pannek, Prof",
Swiss Paraplegic Centre,Nottwil,Switzerland,Urinary Tract Infection,Role of Residual Urine and Asymptomatic Prostatitis in the Development of Lower Urinary Tract Infections in Spinal Cord Injury Patients - a Prospective Study,NCT01601041,,"PRINCIPAL_INVESTIGATOR: Jürgen Pannek, Prof. (Swiss Paraplegic Center, Nottwil, Switzerland)",,,
Swiss Paraplegic Centre,Nottwil,Switzerland,Spinal Cord Injury; Neurogenic Detrusor Overactivity; Neurogenic Lower Urinary Tract Dysfunction,Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?,NCT02138149,,,,,
Swiss Paraplegic Centre,Nottwil,Switzerland,Spinal Cord Injury; Neurogenic Lower Urinary Tract Dysfunction,Representation of the Bladder Innervation Using Diffusion Tensor Imaging Fiber Tracking With MRI - a Pilot Study,NCT02138201,,,,,
Swiss Paraplegic Centre,Nottwil,Switzerland,Neurogenic Lower Urinary Tract Dysfunction,Somatosensory Evoked Potentials From the Lower Urinary Tract in Individuals With Neurogenic Lower Urinary Tract Dysfunction as a Result of Spinal Cord Injury,NCT02449512,,PRINCIPAL_INVESTIGATOR: Jens Wöllner (Swiss Paraplegic Centre),,,
Swiss Paraplegic Centre,Nottwil,Switzerland,Bladder Cancer; Spinal Cord Injury,Quantitative Evaluation of a Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer,NCT02538809,,PRINCIPAL_INVESTIGATOR: Jens Wöllner (Schweizer Paraplegiker-Zentrum Nottwil),,,
Swiss Paraplegic Centre,Nottwil,Switzerland,"Spinal Cord Injuries; Bladder, Neurogenic",Feasibility of Detecting Functional Changes in the Brain After Tibial Nerve Stimulation and the Association with the Sacral Roots Architecture: a Pilot Magnetic Resonance Study,NCT03908047,,"PRINCIPAL_INVESTIGATOR: Jens Wöllner, Dr. (Senior Consultant Neuro-Urology)",,,
Swiss Paraplegic Centre,Nottwil,Switzerland,"Spinal Cord Injury, Acute","Transcutaneous Tibial Nerve Stimulation in Patients with Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: a Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial",NCT03965299,RECRUITING,"STUDY_CHAIR: Thomas M. Kessler, Prof. Dr. med. (University of Zurich); PRINCIPAL_INVESTIGATOR: Thomas M. Kessler, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Armin Curt, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Martin Brinkhof, Dr. (Swiss Paraplegic Research, Nottwil); PRINCIPAL_INVESTIGATOR: Jürgen Pannek, Prof. Dr. med. (Swiss Paraplegic Centre)","CONTACT: Thomas M. Kessler, Prof. Dr. med.; CONTACT: Martina D. Liechti, Dr. sc. ETH","CONTACT: Jürgen Pannek, Prof. Dr. med.; CONTACT: Jürgen Pannek, Prof. Dr. med.",
Swiss Paraplegic Centre Nottwil,Nottwil,Switzerland,Refractory Neurogenic LUTD,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial",NCT02165774,,,,,
Swiss paraplecic centre,Nottwil,Switzerland,Spinal Cord Injury,Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Due to Spinal Cord Injury,NCT01299792,,"PRINCIPAL_INVESTIGATOR: Juergen Pannek, MD (Swiss Paraplegic Centre)",,,
Cantonal Hospital St. Gallen,Sankt Gallen,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
"Spinal Cord Injury Department, Clinique romande de réadaption",Sion,Switzerland,"Spinal Cord Injury, Acute","Transcutaneous Tibial Nerve Stimulation in Patients with Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: a Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial",NCT03965299,RECRUITING,"STUDY_CHAIR: Thomas M. Kessler, Prof. Dr. med. (University of Zurich); PRINCIPAL_INVESTIGATOR: Thomas M. Kessler, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Armin Curt, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Martin Brinkhof, Dr. (Swiss Paraplegic Research, Nottwil); PRINCIPAL_INVESTIGATOR: Jürgen Pannek, Prof. Dr. med. (Swiss Paraplegic Centre)","CONTACT: Thomas M. Kessler, Prof. Dr. med.; CONTACT: Martina D. Liechti, Dr. sc. ETH","CONTACT: Xavier Jordan, Dr. med.; CONTACT: Xavier Jordan, Dr. med.",
Cantonal Hospital of St. Gallen,St. Gallen,Switzerland,Refractory Neurogenic LUTD,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial",NCT02165774,,,,,
Cantonal Hospital Winterthur,Winterthur,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
Balgrist University Hospital,Zurich,Switzerland,Neurogenic Detrusor Overactivity; Spinal Cord Injury,Therapeutic Effects of Early and Late Onset Peripheral Pudendal Neurostimulation on Bladder Function and Autonomic Neuroplasticity in SCI - a Controlled European Multicenter Study,NCT01043848,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, MD (University of Zurich); PRINCIPAL_INVESTIGATOR: Martin Schubert, MD (Balgrist University Hospital)",,,
Balgrist University Hospital,Zurich,Switzerland,Spinal Cord Injuries; Neurogenic Bladder Dysfunction; Degenerative Cervical Spinal Stenosis,Functional and Structural Changes in the Central Nervous System Following Spinal Cord Injury,NCT05681936,RECRUITING,"PRINCIPAL_INVESTIGATOR: Patrick Freund, Prof. Dr. med. Dr. rer. nat. (University of Zurich)","CONTACT: Gergely David, Dr.; CONTACT: Christian Kuendig, MSc","CONTACT: Gergely David, Dr.; CONTACT: Christian Kuendig, MSc",
"University of Zurich, Balgrist University Hospital, Spinal Cord Injury Center",Zurich,Switzerland,Refractory Neurogenic LUTD,"Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial",NCT02165774,,,,,
Balgrist University Hospital,Zürich,Switzerland,Neurogenic Bladder Dysfunction,"Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial",NCT04315142,,,,,
"Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital",Zürich,Switzerland,"Spinal Cord Injury, Acute","Transcutaneous Tibial Nerve Stimulation in Patients with Acute Spinal Cord Injury to Prevent Neurogenic Detrusor Overactivity: a Nationwide Randomised, Sham-controlled, Double-blind Clinical Trial",NCT03965299,RECRUITING,"STUDY_CHAIR: Thomas M. Kessler, Prof. Dr. med. (University of Zurich); PRINCIPAL_INVESTIGATOR: Thomas M. Kessler, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Armin Curt, Prof. Dr. med. (Balgrist University Hospital); PRINCIPAL_INVESTIGATOR: Martin Brinkhof, Dr. (Swiss Paraplegic Research, Nottwil); PRINCIPAL_INVESTIGATOR: Jürgen Pannek, Prof. Dr. med. (Swiss Paraplegic Centre)","CONTACT: Thomas M. Kessler, Prof. Dr. med.; CONTACT: Martina D. Liechti, Dr. sc. ETH","CONTACT: Thomas M Kessler, Prof. Dr. med.; CONTACT: Thomas M Kessler, Prof. Dr. med.",
"Neuro-Urology, Spinal Cord Injury Center & Research, Balgrist University Hospital",Zürich,Switzerland,"Urinary Bladder, Neurogenic; Neuropathic Bladder","Is the Detrusor Contraction During the Ice-water-test Provoked by the Ice Water or the Rapid Bladder Filling? A Randomized, Double-blind Clinical Trial",NCT01773213,,,,,
"Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Neurogenic Lower Urinary Tract Dysfunction; Multiple Sclerosis; Overactive Bladder; Spinal Cord Injury,The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques,NCT01768910,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, MD (Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland); PRINCIPAL_INVESTIGATOR: Thomas M Kessler, MD (Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland); PRINCIPAL_INVESTIGATOR: Spyros Kollias, MD (Institute of Neuroradiology, University Hospital Zurich, Sternwartstrasse 6, 8091 Zurich, Switzerland)",,,
Novartis Investigative Site,Zürich,Switzerland,"Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic","A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy",NCT01598103,,STUDY_DIRECTOR: Novartis Pharmaceuticals (Novartis Pharmaceuticals),,,
"Spinal Cord Injury & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Healthy; Nonneurogenic Neurogenic Bladder Dysfunction; Neurogenic Bladder Dysfunction Nos,Investigation of Lower Urinary Tract Afferent and Cortical Brain Activity During Lower Urinary Tract Stimulation Using Electroencephalogram Measurements,NCT01389921,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, Dr. (Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital)",,,
"Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Neurogenic Bladder; Diseases of the Lower Urinary Tract: General Conditions,Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich,NCT01293110,RECRUITING,PRINCIPAL_INVESTIGATOR: Thomas M Kessler (Universitätsklinik Balgrist),"CONTACT: Thomas M Kessler, MD","CONTACT: Thomas M Kessler, MD",
"Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Neurogenic Bladder,Incidence of Urinary Tract Infection and Germ Identification After Urodynamic Investigation in Patients With Spinal Cord Injury,NCT01297647,,,,,
"Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Urinary Bladder Neurogenic Dysfunction,Neuro-urological Outcome After Spinal Cord Injury,NCT01297660,,"PRINCIPAL_INVESTIGATOR: Jens Wöllner, Dr. med. (Balgrist University Hospital)",,,
"Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,Vesico-ureteral Reflux; Spinal Cord Injury,Vesico-ureteral Reflux in a Contemporary Series of Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction,NCT01297673,,,,,
"Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital",Zürich,Switzerland,"Bladder Disorder, Neurogenic",Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections,NCT01337024,,,,,
University Hospital Zürich,Zürich,Switzerland,Neurogenic Lower Urinary Tract Dysfunction; Multiple Sclerosis; Overactive Bladder; Spinal Cord Injury,The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques,NCT01768910,,"PRINCIPAL_INVESTIGATOR: Ulrich Mehnert, MD (Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland); PRINCIPAL_INVESTIGATOR: Thomas M Kessler, MD (Neuro-Urology, Spinal Cord Injury Center & Research, University of Zurich, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland); PRINCIPAL_INVESTIGATOR: Spyros Kollias, MD (Institute of Neuroradiology, University Hospital Zurich, Sternwartstrasse 6, 8091 Zurich, Switzerland)",,,
Afyonkarahisar Health Sciences University,Afyon,Turkey,Lower Urinary Tract Symptoms,The Effect of Repetative Transcranial Magnetic Stimulation Therapy on Lower Urinary System Dysfunctions in Stroke Patients,NCT05738863,RECRUITING,,"CONTACT: Ayşenur Beysel, MD; CONTACT: Hilal Yeşil, MD","CONTACT: Ayşenur Beysel, MD; CONTACT: Hilal Yeşil, MD",
Hilal Yesil,Afyonkarahisar,Turkey,Lower Urinary Tract Symptoms,"The Course of Post-stroke Bladder Problems and Their Relation With Functional, Mental Status and Quality of Life: A Six-month Prospective, Multicenter Study",NCT03174600,,,,,
,Ankara,Turkey,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00575016,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Ankara Gaziler Physical Therapy and Rehabilitation Training and Research Hospital,Ankara,Turkey,Neurogenic Bladder; Spinal Cord Injury; Intermittent Catheterization; Mobile Application,The Effects of CIC Training With a Mobile Application on Quality of Life and Compliance in Spinal Cord Injury Patients: a Single Blind Randomized Controlled Study (CIC: Clean Intermittent Catheterization),NCT06429631,,"PRINCIPAL_INVESTIGATOR: NURCAN ÇALIŞKAN, Prof. Dr (Gazi University); PRINCIPAL_INVESTIGATOR: BİLGE YILMAZ, Prof. Dr. (SBÜ GAZİLER FİZİK TEDAVİ VE REHABİLİTASYON EĞİTİM VE ARAŞTIRMA HASTANESİ); STUDY_CHAIR: Nilgün Aras, Phd student (SBÜ GAZİLER FİZİK TEDAVİ VE REHABİLİTASYON EĞİTİM VE ARAŞTIRMA HASTANESİ)",,,
Ankara Yildirim Beyazit University,Ankara,Turkey,Lower Urinary Tract Symptoms,Effects of Digital Pelvic Floor Muscle Training and Lifestyle Recommendations in Patients With Multiple Sclerosis Having Lower Urinary Tract Symptoms,NCT04759391,,PRINCIPAL_INVESTIGATOR: Seyda Toprak Celenay (Ankara Yildirim Beyazıt University),CONTACT: Seyda Toprak Celenay,CONTACT: Seyda Toprak Celenay,
Ankara Üniversitesi Tıp Fakültesi,Ankara,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Gaziler PMR, Training and Research Hospital, Department of PMR",Ankara,Turkey,"Incontinence, Urge; Stroke; Neurogenic Bladder",Evaluation of the Efficacy of Transcutaneous Tibial Nerve Stimulation on Post-Stroke Overactive Bladder,NCT06247033,,"PRINCIPAL_INVESTIGATOR: Umay Ekinci, MD (University of Health Sciences, Department of PM&R)",,,
Medipol Mega University Hospital,Bagcilar,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Uludag Universitesi Tip Fakultesi, Uroloji Anabilim Dali, Gorukle",Bursa,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Pamukkale University,Denizli,Turkey,"Urinary Bladder, Overactive",Efficacy of Transcutaneous Tibial Nerve Stimulation in Patients With Neurogenic Overactive Bladder After Stroke: A Randomized Placebo-controlled Clinical Trial.,NCT06385769,,"STUDY_DIRECTOR: Necmettin Yıldız, Prof. (Pamukkale University)","CONTACT: Emre Bezmez, M.D.",,
Tuba Maden,Gaziantep,Turkey,Multiple Sclerosis; Pelvic Floor Disorders; Urinary Incontinence; Visceral Mobilization; Osteopathic Manipulative Treatment,"Acute Effect of Osteopathic Visceral Mobilization Techniques on Adductor Spasticity, Incontinence and Constipation in Multiple Sclerosis Patients",NCT05981339,RECRUITING,,CONTACT: Tuba Maden,CONTACT: Tuba Maden,
Suleyman Demirel University,Isparta,Turkey,Stroke; Urinary Incontinence; Motor Skills Disorders,The Relationship Between Urinary Incontinence and Motor Symptoms in Individuals With Stroke,NCT06333119,,STUDY_DIRECTOR: Pinar Yasar (Suleyman Demirel University),,,
Bakirkoy Dr. Sadi Konuk Research and Training Hospital,Istanbul,Turkey,Multiple Sclerosis; Lower Urinary Tract Symptoms,Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation in Multiple Sclerosis Patients With Lower Urinary Track Symptoms: A Sham Controlled Prospective Randomized Controlled Study,NCT06263556,RECRUITING,PRINCIPAL_INVESTIGATOR: Sibel CAGLAR (Bakirkoy Dr. Sadi Konuk Research and Training Hospital); STUDY_CHAIR: Arda can Kasap (Bakirkoy Dr. Sadi Konuk Research and Training Hospital),CONTACT: Sibel CAGLAR; CONTACT: Arda Can KASAP,CONTACT: Sibel CAGLAR; CONTACT: Arda Can KASAP,
Istanbul Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi Merdivenköy Mah,Istanbul,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Istanbul Medipol Mega University Hospital,Istanbul,Turkey,Neurogenic Bladder Dysfunction,The Effect of Different Neuromodulation Techniques in the Treatment of Multiple Sclerosis Patients With Neurogenic Bladder Dysfunction,NCT05312138,,PRINCIPAL_INVESTIGATOR: Pınar Atak Çakır,,,
Istanbul Physical Medicine and Rehabilitation Training and Research Hospital,Istanbul,Turkey,"Stroke, Complication; Neurogenic Bladder",The Effects of Stroke Related Neurogenic Bladder on The Quality of Life: A Study of Turkish Population,NCT04072796,,"STUDY_CHAIR: Kadriye Önes, Prof (Istanbul Physical Medicine Rehabilitation Training and Research Hospital)",,,
Koç University,Istanbul,Turkey,Multiple Sclerosis; Neurogenic Bladder,Optimal Diagnostic Algorithm for Neurogenic Lower Urinary Tract Symptoms in Patients With MS,NCT05587101,RECRUITING,PRINCIPAL_INVESTIGATOR: Ersin Köseoğlu (Koç University),CONTACT: Tufan Tarcan; CONTACT: Ersin Köseoğlu,CONTACT: Hakan Orer,
Marmara Üniversitesi Eğitim ve Araştırma Hastanesi,Istanbul,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Prof.Dr.Cemil Taşcıoğlu Şehir Hastanesi,Istanbul,Turkey,Multiple Sclerosis; Overactive Bladder Syndrome,Effect of Transcutaneous Posterior Tibial Nerve Stimulation and Parasacral Transcutaneous Electrical Stimulation on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.,NCT06143397,RECRUITING,,"CONTACT: Büşra Aydın Erkılıç, MSc",CONTACT: Büşra aydın erkılıç,
"Dokuz Eylul University Hospital, MS Outpatient Clinic",Izmir,Turkey,Multiple Sclerosis; Urinary Incontinence,"Effects of Telerehabilitation-Based Pelvic Floor Muscle Training on Urinary Incontinence, Sexual Function and Quality of Life in People With Multiple Sclerosis",NCT04758468,,,,,
Erciyes Üniversitesi Tıp Fakültesi,Kayseri,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Kocaeli Üniversitesi Tıp Fakültesi,Kocaeli,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Kutahya Health Sciences University,Kutahya,Turkey,Lower Urinary Track Symptoms; Multiple Sclerosis,Turkish Validity and Reliability of the Core Lower Urinary Tract Symptoms Questionnaire in Patients With Multiple Sclerosis,NCT06599866,,,,,
Celal Bayar Universitesi Hafsa Sultan Hastanesi,Manisa,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
"Bolu Abant İzzet Baysal University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation",Merkez,Turkey,Multiple Sclerosis; Urinary Incontinence; Lower Urinary Tract Symptoms,"Investigation of the Effects of Spinal Stabilization Exercises Focusing on the Pelvic Floor on Core Stability, Urinary Symptoms, and Pelvic Floor Muscle Function in Women With Multiple Sclerosis and Lower Urinary Tract Symptoms",NCT07074587,,"PRINCIPAL_INVESTIGATOR: gözde tekin, Msc (Abant Izzet Baysal University)",,,
Afitap ÖZDELİKARA,Samsun,Turkey,Multiple Sclerosis; Reflexology; Urinary Incontinence,The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients,NCT05541965,,,,,
Ondokuz Mayıs Üniversitesi Tıp Fakültesi,Samsun,Turkey,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660138,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Tokat Gaziosmanpaşa University,Tokat,Turkey,Multiple Sclerosis; Urinary Incontinence,The Effect of Health Belief Model-Based Pelvic Floor Muscle Exercise Training on Urinary Incontinence and Quality of Life in Female Patients With Multiple Sclerosis,NCT06805331,,,"CONTACT: Nurgül KAPLAN, Lecturer; CONTACT: Mehtap TAN, Professor Doctor",,
Mehmet Akif Guler,İstanbul,Turkey,Spinal Cord Injuries,"Turkish Version of the Neurogenic Bladder Symptom Score Questionnaire: a Cross-cultural Adaptation, Reliability and Validity Study",NCT03964077,,,,,
Pelin Pişirici,İstanbul,Turkey,Bladder Dysfunction; Bowel Dysfunction; Cerebral Palsy; Neurogenic Bladder; Neurogenic Bowel,Comparison the Efficiency of Transcutaneous Electrical Nerve Stimulation and Manual Therapy in Children With Cerebral Palsy With Lower Urinary System Dysfunction,NCT05351138,,"PRINCIPAL_INVESTIGATOR: Betül Ünal, PT (Bahçeşehir University, Graduate Education Institute, Physical Therapy and Rehabilitation); STUDY_DIRECTOR: Pelin Pişirici, PT, PHD (Bahçeşehir University, Health Sciences Faculty, Physiotherapy and Rehabilitation Department); STUDY_CHAIR: Halil Tuğtepe, MD, Prof. (Private Tuğtepe Pediatric Urology and Surgery Clinic); STUDY_CHAIR: Aygül Köseoğlu, PT, Msc (Private Tuğtepe Pediatric Urology and Surgery Clinic)",,,
"Municipal Healthcare Institution ""Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval"", Urology Department",Kharkiv,Ukraine,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Kiev,Ukraine,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Kiev City Clinical Hospital No. 3,Kiev,Ukraine,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
,Lviv,Ukraine,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
NHS Grampian - Aberdeen Royal Infirmary,Aberdeen,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Stoke Mandeville Hospital,Aylesbury,United Kingdom,UTI; Neurogenic Bladder; Antibiotic Resistance,Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study,NCT02591901,,"PRINCIPAL_INVESTIGATOR: Maurizio Belci, DMS MSc MRCS FRCP (Stoke Mandeville Hospital)",,,
NHS Ayrshire and Arran,Ayrshire,United Kingdom,Stroke; Urinary Incontinence,A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.,NCT02239796,,PRINCIPAL_INVESTIGATOR: Joanne Booth (Glasgow Caledonian University),,,
Bedford Hospital,Bedford,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
North Bristol NHS Trust | Southmead Hospital - Research and Development - Urology Department,Bristol,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Kent and Canterbury Hospital | Renal Research Delivery Team,Canterbury,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
,Cardiff,United Kingdom,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
Broomfield Hospital,Chelmsford,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
"Department of Neurosciences, Western General Hospital",Edinburgh,United Kingdom,Cauda Equina Syndrome; Functional Neurological Disorder,BLB Study Back or Leg Pain and Bladder Symptoms Study,NCT03325374,,PRINCIPAL_INVESTIGATOR: Ingrid Hoeritzauer (University of Edinburgh),,,
NHS Lanarkshire,Glasgow,United Kingdom,Stroke; Urinary Incontinence,A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.,NCT02239796,,PRINCIPAL_INVESTIGATOR: Joanne Booth (Glasgow Caledonian University),,,
,London,United Kingdom,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00311376,,STUDY_DIRECTOR: Medical Director (Allergan),,,
,London,United Kingdom,Overactive Bladder,A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis,NCT00876447,,STUDY_DIRECTOR: Medical Director (Allergan),,,
"Guy's and St Thomas' Foundation Trust | Guy's Hospital - Transplant, Renal and Urology Research",London,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
King's College Hospital NHS Foundation Trust | King's College Hospital - Renal Research Department,London,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
National Hospital for Neurology and Neurosurgery,London,United Kingdom,Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",NCT01023269,,"PRINCIPAL_INVESTIGATOR: Michele Spinelli, MD (Ospedale Niguarda Ca' Granda, Milan, Italy); PRINCIPAL_INVESTIGATOR: Karel Everaert, MD (University Ghent); PRINCIPAL_INVESTIGATOR: Philip Van Kerrebroeck, MD (Academisch Ziekenhuis, Maastricht, The Netherlands); PRINCIPAL_INVESTIGATOR: Emmanuel Chartier-Kastler, MD (Hôpital de la Pitié Salpétrière, Paris, France); PRINCIPAL_INVESTIGATOR: Arndt Van Ophoven, MD (Marienhospital Herne Klinikum der Ruhr-Universität, Herne, Germany); PRINCIPAL_INVESTIGATOR: Karl Sievert, MD (Klinik für Urologie Oberarzt-Sekretariat, Tübingen, Germany); PRINCIPAL_INVESTIGATOR: Suzy Elneil, MD (National Hospital for Neurology and Neurosurgery, London, UK)",,,
National Hospital for Neurology and Neurosurgery,London,United Kingdom,Overactive Bladder; Multiple Sclerosis,Single Centre Randomised Pilot Study of Two Regimens (30mins Daily or Weekly for 12 Weeks) of Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome,NCT02790307,,"PRINCIPAL_INVESTIGATOR: Jalesh Panicker, FRCP (National Hospital for Neurology and Neurosurgery)",,,
National Hospital for Neurology and Neurosurgery - UCL,London,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Royal Free Hospital Hampstead NHS Trust,London,United Kingdom,Secondary Progressive Multiple Sclerosis,"A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis",NCT01228396,,"PRINCIPAL_INVESTIGATOR: James Malone-Lee, MD (University College, London)",,,
"University College of London, Institute of Neurology",London,United Kingdom,Bladder Dysfunction; Multiple Sclerosis,Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis,NCT00913510,,"PRINCIPAL_INVESTIGATOR: Clare Fowler, Prof. (University College, London)",,,
Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Urology Department,Newcastle,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
,Newcastle Upon Tyne,United Kingdom,Multiple Sclerosis; Neurogenic Bladder; Spinal Cord Diseases,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity",NCT00629642,,PRINCIPAL_INVESTIGATOR: Department of (Neuro) Urology (Universitaire Ziekenhuizen KU Leuven),,,
"Institute of Cellular Medicine, Newcastle University",Newcastle upon Tyne,United Kingdom,"Urinary Tract Infections, Recurrent",Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis,NCT02145338,,"PRINCIPAL_INVESTIGATOR: Robert Pickard, MD (Newcastle University)",,,
Aneurin Bevan University Health Board | Royal Gwent Hospital - Clinical Research Centre,Newport,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Oxford Centre for Enablement,Oxford,United Kingdom,UTI; Neurogenic Bladder; Antibiotic Resistance,Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study,NCT02591901,,"PRINCIPAL_INVESTIGATOR: Maurizio Belci, DMS MSc MRCS FRCP (Stoke Mandeville Hospital)",,,
University of Oxford,Oxford,United Kingdom,Bladder Dysfunction; Spinal Cord Injuries,Restoration of Bladder Function in Spinal Cord Injury,NCT05968352,RECRUITING,,,"CONTACT: Alexander L Green, PhD; CONTACT: Alex Fung, MB BS",
,Scunthorpe,United Kingdom,Overactive Bladder,Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder,NCT00461292,,STUDY_DIRECTOR: Medical Director (Allergan),,,
Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital,Sheffield,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Southampton General Hospital,Southampton,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Mid and South Essex NHS Foundation Trust | Southend University Hospital - Research & Development,Southend-on-Sea,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Royal National Orthopaedic Hospital,Stanmore,United Kingdom,Spinal Cord Injuries; Neurogenic Bladder; Neurogenic Detrusor Overactivity; Neurogenic Bladder Dysfunction,NEUROMOD UCon: Pilot Study of Dorsal Genital Nerve Stimulation for Management of Bladder Overactivity Following Spinal Cord Injury,NCT05502614,,"PRINCIPAL_INVESTIGATOR: Lynsey Duffell, PhD (University College, London)",,,
Royal National Orthopaedic Hospital,Stanmore,United Kingdom,Spinal Cord Injuries,Promoting Restoration of Function of Co-ordinated Bladder Storage and Voiding Following Spinal Cord Injury by Combination of Transcutaneous Spinal Cord Stimulation and Bladder & Pelvic Floor Muscle Training Training,NCT05504200,,PRINCIPAL_INVESTIGATOR: Frank Lee (Royal National Orthopaedic Hospital),,,
Royal National Orthopaedic Hospital,Stanmore,United Kingdom,Spinal Cord Injuries; Neuromodulation; Neurogenic Bladder; Neurogenic Bowel; Neurogenic Detrusor Overactivity,Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury,NCT06515223,RECRUITING,"PRINCIPAL_INVESTIGATOR: David Baxter, MD (National Health Service, United Kingdom)","CONTACT: Lynsey Duffell, PhD; CONTACT: Hannah Houliston, PhD","CONTACT: Hannah Houliston, PhD",
Royal National Orthopaedic Hospital Trust,Stanmore,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
Stockport NHS Foundation Trust | Stepping Hill Hospital - Research and Innovation Department,Stockport,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Sunderland Royal Hospital,Sunderland,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
Mid Yorkshire Teaching NHS Trust | Pinderfields Hospital - Yorkshire Regional Spinal Injuries Centre,Wakefield,United Kingdom,Bladder Outlet Obstruction; Multiple Sclerosis; Cauda Equina Syndrome; Enlarged Prostate With Lower Urinary Tract Symptoms; Parkinson Disease; Lower Urinary Tract Symptoms; Detrusor Underactivity; Spinal Cord Injuries,A Multi-centre Prospective Observational Study of the User Experience of Catheterisation and Quality of Life in Patients Prescribed GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology,NCT05470751,,PRINCIPAL_INVESTIGATOR: Chris Harding (Site Investigator - Newcastle),,,
The Mid Yorkshire Hospitals NHS Trust - Pinderfields Hospital,Wakefield,United Kingdom,Urinary Incontinence; Overactive Bladder,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",NCT02660359,,STUDY_DIRECTOR: Ipsen Medical Director (Ipsen),,,
